source
- Expert outlines how to manage common skin and GI side effects of daraxonrasib in pancreatic cancerDr Pant, MD, a professor at MD Anderson Cancer Center, discussed the safety profile of daraxonrasib, a RAS(ON) multi-selective inhibitor being studied in pancreatic ductal adenocarcinoma. The drug…
- Pfizer CEO Albert Bourla rules out any transformative merger plansOn the May 5, 2026 earnings call, Pfizer chief Albert Bourla was asked whether the company was considering a transformative merger in the near or medium term. Bourla answered that Pfizer has no pl…